Innate Pharma (IPHA) Equity Average (2018 - 2025)

Innate Pharma has reported Equity Average for 7 years, with the latest figure at -$9.7 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 148.06% year-over-year to -$9.7 million; the trailing twelve-month figure through Dec 2025 stood at -$9.7 million (down 148.06% YoY), and the FY2025 full-year result was -$7.9 million, down 124.24% from the prior year.
• Equity Average for Q4 2025 stood at -$9.7 million, down from $7.6 million in the prior quarter.
• The five-year high for Equity Average was $173.4 million in Q2 2021, with the low at -$9.7 million in Q4 2025.
• Historically, Equity Average has averaged $70.9 million across 5 years, with a median of $59.3 million in 2023.
• Annual changes were most pronounced in 2024 — Equity Average retreated 26.56% — and 2025, when it tumbled 148.06%.
• Innate Pharma's Equity Average stood at $141.9 million in 2021, then tumbled by 36.78% to $89.7 million in 2022, then tumbled by 33.74% to $59.4 million in 2023, then tumbled by 65.97% to $20.2 million in 2024, then plunged by 148.06% to -$9.7 million in 2025.
• The last three Equity Average figures came in at -$9.7 million (Q4 2025), $7.6 million (Q2 2025), and $20.2 million (Q4 2024), per Business Quant data.